|1.||Conn, P Jeffrey: 6 articles (01/2011 - 02/2006)|
|2.||Gao, Wen-Jun: 3 articles (11/2015 - 05/2011)|
|3.||Neale, Joseph H: 3 articles (04/2012 - 01/2010)|
|4.||Markou, Athina: 3 articles (01/2011 - 08/2010)|
|5.||Jones, Carrie K: 3 articles (01/2009 - 01/2005)|
|6.||Li, Meng-Lin: 2 articles (11/2015 - 07/2015)|
|7.||Hu, Xi-Quan: 2 articles (11/2015 - 07/2015)|
|8.||Li, Feng: 2 articles (11/2015 - 07/2015)|
|9.||Li, Yan-Chun: 2 articles (11/2015 - 05/2011)|
|10.||Huang, Xu-Feng: 2 articles (11/2014 - 05/2011)|
|1.||Schizophrenia (Dementia Praecox)
12/01/2010 - "These procognitive effects may contribute to the therapeutic efficacy of agents stimulating mGluR2 in schizophrenia."
06/01/2011 - "Metabotropic glutamate receptors 2/3 (mGlu(2/3)) have been implicated in schizophrenia and as a novel treatment target for schizophrenia. "
07/01/2006 - "Thus, targeting mGluR2/3s might be a novel treatment for several psychiatric disorders associated with inappropriate glutamatergic neurotransmission, such as schizophrenia. "
07/03/2015 - "Until the mechanisms associated with mGluR2/3 are clearly elucidated and all treatment options are tested, it would be a great mistake to terminate the study of mGluR2/3 as a therapeutic target for schizophrenia. "
03/01/2001 - "We genotyped 213 Japanese schizophrenics and 220 controls to study the association of polymorphisms in the mGluR2 gene with schizophrenia. "
04/01/2004 - "The present study, therefore, suggests that the reduction of mGluR2/3 immunopositive product in the SLM of CA1 is a consequence of neuronal loss in either the entorhinal cortex or CA1 area of the hippocampus, and at the dosage range from 12.5 to 600 mg/kg, (2R,4R)-APDC may not be effective in the prevention of seizures or neuronal death in the hilus of the dentate gyrus."
09/01/2006 - "We conclude by reviewing the potential advantages of Group II mGluRs, specifically mGluR2, in the treatment of both convulsive and non-convulsive seizures."
06/01/1994 - "(S)-4-carboxy-3-hydroxyphenylglycine, an antagonist of metabotropic glutamate receptor (mGluR) 1a and an agonist of mGluR2, protects against audiogenic seizures in DBA/2 mice."
01/01/2011 - "The present study was undertaken to clarify the effects of (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA), a metabotropic glutamate receptor (mGluR) 1 antagonist, (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate ((2R,4R)-APDC), a mGluR2/3 agonist, and L-(+)-2-amino-4-phosphonobutyric acid (L-AP4), a mGluR4/8 agonist, on pentetrazol-induced kindled seizures. "
12/01/1998 - "(2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine (PCCG-IV), which is a potent mGluR2 antagonist and a group III mGluR agonist at higher doses, increased the PTZ-induced seizure latency (ED50=51 nmol) and this effect was fully reversed by the group III mGluR antagonist, (S)-2-amino-2-methyl-4-phosphonobutanoic acid (MAP4). "
|3.||Anxiety Disorders (Anxiety Disorder)
07/01/2006 - "These results suggest that the blockade of mGluR2/3 with MGS0039 may be effective in the treatment of depressive and anxiety disorders."
08/01/2010 - "It also reviews evidence that group II mGluR agonists and positive allosteric modulators as well as group I mGluR antagonists might also treat anxiety disorders and some forms of depression, while mGluR2 and group I mGluR antagonists (particularly mGluR5 antagonists) might have antidepressant properties. "
06/01/2008 - "LY354740, a potent and selective mGlu (metabotropic glutamate receptor)2/3 agonist, has shown efficacy in the treatment of generalized anxiety disorder (GAD). "
07/01/2006 - "Previous studies indicate that agonists of the group II metabotropic glutamate receptors (mGluRs), mGluR2 and mGluR3, may provide a novel approach for the treatment of anxiety disorders and schizophrenia. "
09/01/2005 - "Eli Lilly and Co is developing LY-544344, a prodrug of the metabotropic glutamate receptor 2/3 agonist LY-354740, for the potential treatment of anxiety disorders."
01/01/2010 - "Group II metabotropic glutamate receptors (mGluR2/3) play a role in pain processing in the laterocapsular part of the central nucleus of the amygdala (CeLC). "
05/29/2009 - "We further investigated the possible involvement of mGluR2/3 and mechanisms underlying peripheral inflammatory pain induced by subcutaneous complete Freund's adjuvant (CFA) injection. "
01/01/2005 - "Group II (mGluR2/3) metabotropic glutamate receptors have been implicated in the mechanisms of persistent pain states. "
01/01/2010 - "Given the high concentration of NAAG in the amygdala and its activation of group II mGluRs (mGluR3 > mGluR2), this study was undertaken using the mouse formalin model of inflammatory pain to test the hypothesis that NAAG influences pain processing in the amygdala. "
02/20/2006 - "This study investigated the effects of an intrathecal mGluR2/3 agonist, APDC, and a mGluR2/3 antagonist, LY341495, for inflammatory and acute pain in the formalin test and thermal stimulation test. "
|5.||Parkinson Disease (Parkinson's Disease)
01/01/2010 - "Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease."
09/01/2002 - "Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease."
01/01/2011 - "MGluR2 is G protein-coupled receptor that is targeted for diseases like anxiety, depression, Parkinson's disease and schizophrenia. "
09/01/2002 - "The aim of the present studies was to examine the ability of a potent, systemically active, selective Group II mGlu receptor (mGluR2/3) agonist, 1R,4R,5S,6R-2-oxa-4-minobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) to provide both functional relief and neuroprotection in rodent models of Parkinson's disease (PD). "
04/01/2009 - "Modulation of basal ganglia group II metabotropic glutamate receptors (mGluR2/3) is a potential therapeutic alternative to levodopa in Parkinson disease (PD). "
|1.||metabotropic glutamate receptor 3 (mGluR3)
|2.||metabotropic glutamate receptor 2
|3.||Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)
|4.||metabotropic glutamate receptor 5
|5.||metabotropic glutamate receptor type 1
|6.||Glutamate Carboxypeptidase II (N-Acetylaspartylglutamate Peptidase)
|8.||2- amino- 3- (3,4- dichlorobenzyloxy)- 6- fluorobicyclo(3.1.0)hexane- 2,6- dicarboxylic acid
|3.||Self Administration (Administration, Self)
|4.||Drug Therapy (Chemotherapy)